Contrasting Atrion (NASDAQ:ATRI) and Arch Therapeutics (NASDAQ:ARTH) – Enterprise Echo

Atrion (NASDAQ:ATRI) and Arch Therapeutics (OTCMKTS:ARTH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Valuation & Earnings

This table compares Atrion and Arch Therapeutics revenue, earnings per share (EPS) and valuation.

Volatility & Risk

Atrion has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, Arch Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500.

Institutional & Insider Ownership

66.6% of Atrion shares are owned by institutional investors. Comparatively, 0.0% of Arch Therapeutics shares are owned by institutional investors. 22.1% of Atrion shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Atrion and Arch Therapeutics, as provided by MarketBeat.

Arch Therapeutics has a consensus target price of $1.63, indicating a potential upside of 636.96%. Given Arch Therapeutics higher probable upside, analysts plainly believe Arch Therapeutics is more favorable than Atrion.

Profitability

This table compares Atrion and Arch Therapeutics net margins, return on equity and return on assets.

Summary

Atrion beats Arch Therapeutics on 7 of the 10 factors compared between the two stocks.

Atrion Company Profile

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise MPS2 Myocardial Protection System that delivers fluids and medications, mixes critical drugs, and controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measures the activated clotting time of blood; and a line of products designed for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; one-way and two-way pressure relief valves that protect sensitive electronics; and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales personnel, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

Arch Therapeutics Company Profile

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.

More here:
Contrasting Atrion (NASDAQ:ATRI) and Arch Therapeutics (NASDAQ:ARTH) - Enterprise Echo